Objective: The study aimed to investigate the effectiveness of anisodamine hydrobromide combined with heparin in the treatment of septic shock, in the hope that the therapy will provide alternatives to the treatment of septic shock.~Methods: The study is a multi-center randomized controlled clinical trial. Study population will include critically ill patients with septic shock requiring vasopressor use. The critically ill patients with septic shock will be randomly assigned to four groups in a ratio of 1:1:1:1. The groups will consist of the conventional treatment group, the anisodamine hydrobromide treatment group, the heparin treatment group, and the anisodamine hydrobromide combined with heparin treatment group.~Interim analysis will be performed. The primary study end point is 28-day mortality, and other secondary study endpoints include lactate clearance rate at 6h, 24h, and 72h, ICU mortality, length of stay in ICU and hospital, organ failure free days.~The investigators will appropriately use chi-square test, student t test or rank sum test to compare the differences between the experimental group and the control group.~Discussion: The treatment of anisodamine hydrobromide combined with heparin will be better than the conventional treatment. The study will provide new insight into the treatment of septic shock and can help to reduce mortality rate of septic shock.
The study aimed to investigate the effectiveness of anisodamine hydrobromide combined with heparin in the treatment of septic shock, in the hope that the therapy will provide alternatives to the treatment of septic shock.